The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportChimeric antigen receptor-T cell (CAR-T) therapy is an exciting treatment modality for blood cancers that…
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial…
Today, the global immunotherapy drugs market is valued at €139B ($163B) and is estimated to…
Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come…
Novartis’ Kymriah, one of the first CAR T-cell therapies to be approved to treat blood…
The Dutch startup Neogene Therapeutics has become the second T-cell therapy developer to raise a…
With the help of a huge €66M Series A round last week, the German startup…
The cell and gene therapy sector is booming. At the end of 2019, there were…
